MIF -173G/C polymorphism is associated with NMO disease severity

Area of Science:

• Neuroimmunology
• Genetics
• Neurology

Background:

• Neuromyelitis optica (NMO) is a severe autoimmune disorder affecting the central nervous system.
• Genetic factors contributing to NMO disease progression remain largely unknown.
• Macrophage migration inhibitory factor (MIF) is a key inflammatory cytokine with potential roles in autoimmune diseases.

Purpose of the Study:

• To investigate the association between the macrophage migration inhibitory factor (MIF) -173G/C functional polymorphism and neuromyelitis optica (NMO).
• To explore the relationship between MIF genotypes and clinical characteristics, including disease severity and symptom presentation in NMO patients.

Main Methods:

• Genotyping of the MIF -173G/C polymorphism in NMO patients and healthy controls.
• Analysis of genotype frequencies in relation to NMO diagnosis, clinical phenotypes (optic neuritis, myelitis), and disability scores (e.g., Expanded Disability Status Scale).
• Statistical comparison between patient and control groups, and among subgroups of NMO patients.

Main Results:

• No significant difference in the frequency of high-expression MIF genotypes (CC/GC) was observed between NMO patients and controls, suggesting no link to NMO susceptibility.
• The frequency of high-expression MIF genotypes (CC/GC) was significantly elevated in NMO patients presenting with both optic neuritis and myelitis compared to those with only one symptom.
• Patients with CC/CG MIF genotypes exhibited significantly higher disability scores, indicating a correlation with increased NMO severity.

Conclusions:

• The macrophage migration inhibitory factor (MIF) -173G/C polymorphism is associated with the severity of neuromyelitis optica (NMO), rather than susceptibility to the disease.
• MIF genotypes may influence clinical outcomes and disability progression in NMO patients, particularly those with combined opticospinal and spinal cord involvement.